Перегляд вихідного коду сторінки Adriamycin Outlines Along With Well-Known Myths

855) were 71.4?% and 87.5?%, respectively[24]. In the study by Carri��n et al[25], there was a close correlation of TE with HVPG (r = 0.84, P [https://en.wikipedia.org/wiki/Pentamorphone Pentamorphone] EV and their risk of bleeding. LIVER ELASTOGRAPHY IN THE PREDICTION OF THE PRESENCE OF EV AND THEIR RISK OF RUPTURE Liver stiffness measured by TE showed good results in detecting the presence of EV, with AUROC��s ranging between 0.76 and 0.88[18,26-28]. The cut-offs mentioned by the above studies were 17.6, 21.5, 19 kPa and respectively 19.2 kPa and for these cut-offs the sensitivities were 0.9, 0.76, 0.84 and 0.85 while the specificities were 0.43, 0.78, 0.7 and 0.87. Studies have also shown a correlation between LSM and the size of the EV[27,29,30]. Thus, LSM may be of help in the selection of patients for endoscopic screening for EV and their complications. Liver stiffness may also predict the risk of variceal bleeding by predicting large grade EV (Paquet grade higher or equal to 2), AUROC = 0.85 (95%CI: 0.75-0.94)[28]. [http://www.selleckchem.com/products/Adriamycin.html Topoisomerase inhibitor] Another study found an AUROC of 0.58 (95%CI: 0.48-0.67) for ARFI and [http://www.selleckchem.com/products/LBH-589.html LBH589] 0.53 (95%CI: 0.44-0.63) for TE for predicting variceal bleeding[31] sowing that the two analyzed methods have similar value for this purpose. Elastography may be helpful to screen and identify patients who are at high risk of having large grade EV, which predict variceal bleeding and, therefore, need endoscopic screening. Liver elastography can also be used in combination with other markers (such as spleen diameter and platelet count) to identify more precisely the patients with higher risk for EV bleeding[32]. LIVER ELASTOGRAPHY IN THE PREDICTION OF THE PRESENCE OF HCC Prognosis of patients with chronic liver disease is determined by the extent and progression of liver fibrosis, which may lead to the development of HCC. Liver stiffness is significantly higher in patients with HCC than in patients without HCC[33-35]. However, most of the studies found that liver stiffness alone is insufficient to predict the presence or absence of HCC and that it should be associated in a score with other markers. A score developed by Wong et al[33] based on liver stiffness, age, serum albumin and hepatitis B virus DNA level was found to have AUROC��s of 0.83 to 0.89 in the identification of the HCC patients and a very good negative (99.4%-100%) for the exclusion of HCC in patients. In the study conducted by Feier et al[34], LS was significantly higher (42 kPa vs 27 kPa, P